Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04)

被引：2
作者：
Fontein, D. B. Y. [1 ]
Charehbili, A. [1 ,2 ]
Nortier, J. W. R. [2 ]
Putter, H. [3 ]
Kranenbarg, E. Meershoek-Klein [1 ]
Kroep, J. R. [2 ]
Linn, S. C. [4 ,5 ]
van de Velde, C. J. H. [1 ]
机构：
[1] Leiden Univ, Dept Surg, Med Ctr, POB 9600, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Dept Clin Oncol, Med Ctr, Leiden, Netherlands
[3] Leiden Univ, Dept Med Stat, Med Ctr, Leiden, Netherlands
[4] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[5] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands
来源：
EJSO | 2017年 / 43卷 / 04期
关键词：
Breast cancer; Adverse events; Aromatase inhibitors; Hot flushes; AROMATASE INHIBITORS; TRIAL; TAMOXIFEN; HOT; ARTHRALGIA; RECURRENCE; EFFICACY;
D O I：
10.1016/j.ejso.2016.07.146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: In the adjuvant setting, specific adverse events (AEs) such as vasomotor symptoms (VMS) and musculoskeletal AEs are associated with relapse-free survival in aromatase inhibitor (AI)-treated patients. In the neoadjuvant setting, specific AEs may be associated with tumor response to AIs as well. Methods: Between 2007 and 2012, 107 patients participated in the prospective TEAMIIA trial, a prospective, phase II trial investigating 6 months of neoadjuvant exemestane in patients with strongly ER-positive breast cancer. Radiological response (>= 30% decrease in tumor size) was studied in relation to VMSs and MSAEs. Pearson's Chi-Square tests and multivariate logistic regression analyses were used to evaluate of statistical significance (p < 0.05). Results: Out of 102 patients 26 patients (25.4%) experienced at least one episode of VMS and 27 patients (26.4%) experienced MSAE. Out of 240 reported adverse events, 71 were specific AEs (40 MSAEs, 31 VMSs). Radiological response was greater in patients who reported VMSs compared to patients who did not (70.8% vs. 49.3%, multivariate OR 2.91, 95% C.I. 1.03-8.26, P = 0.045). No significant advantage towards better response was observed in patients who experienced MSAEs (60.0% vs. 53.3%, univariate OR 1.33, 95% C.I. 0.53-3.38, P = 0.545). Conclusion: VMSs are associated with tumor response to neoadjuvant exemestane and may be useful for predicting treatment outcomes of AI treatment at an early stage in patients treated with neoadjuvant AIs. (C) 2016 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码：619 / 624
页数：6
相关论文
共 22 条
[1]   Aromatase inhibitor-associated arthralgia syndrome [J].
Burstein, Harold J. .
BREAST, 2007, 16 (03) :223-234
[2]   Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer [J].
Charehbili, A. ;
Wasser, M. N. ;
Smit, V. T. H. B. M. ;
Putter, H. ;
van Leeuwen-Stok, A. E. ;
Kranenbarg, W. M. Meershoek-Klein ;
Liefers, G. J. ;
van de Velde, C. J. H. ;
Nortier, J. W. R. ;
Kroep, J. R. .
EJSO, 2014, 40 (10) :1216-1221
[3]   Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review [J].
Charehbili, A. ;
Fontein, D. B. Y. ;
Kroep, J. R. ;
Liefers, G. J. ;
Mieog, J. S. D. ;
Nortier, J. W. R. ;
van de Velde, C. J. H. .
CANCER TREATMENT REVIEWS, 2014, 40 (01) :86-92
[4]   Skin blood flow in adult human thermoregulation: How it works, when it does not, and why [J].
Charkoudian, N .
MAYO CLINIC PROCEEDINGS, 2003, 78 (05) :603-612
[5]   Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations [J].
Coleman, R. E. ;
Bolten, W. W. ;
Lansdown, M. ;
Dale, S. ;
Jackisch, C. ;
Merkel, D. ;
Maass, N. ;
Hadji, P. .
CANCER TREATMENT REVIEWS, 2008, 34 (03) :275-282
[6]  
Cortazar P, 2014, LANCET, V12, P9938
[7]   Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial [J].
Cuzick, Jack ;
Sestak, Ivana ;
Cella, David ;
Fallowfield, Lesley .
LANCET ONCOLOGY, 2008, 9 (12) :1143-1148
[8]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[9]   Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation [J].
Felson, DT ;
Cummings, SR .
ARTHRITIS AND RHEUMATISM, 2005, 52 (09) :2594-2598
[10]   Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients [J].
Fontein, D. B. Y. ;
Houtsma, D. ;
Hille, E. T. M. ;
Seynaeve, C. ;
Putter, H. ;
Kranenbarg, E. Meershoek-Klein ;
Guchelaar, H. J. ;
Gelderblom, H. ;
Dirix, L. Y. ;
Paridaens, R. ;
Bartlett, J. M. S. ;
Nortier, J. W. R. ;
van de Velde, C. J. H. .
ANNALS OF ONCOLOGY, 2012, 23 (12) :3091-3097
123